Labour unveils life sciences strategy at Stevenage Bioscience Catalyst

  • Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister launch Life Sciences Strategy at Stevenage Bioscience Catalyst (SBC).
  • Shadow Ministers take part in roundtable discussion with key industry figures including AstraZeneca, GSK, BioIndustry Association (BIA) and Stevenage Bioscience Catalyst and its high growth companies to hear at first hand the opportunities and challenges facing the sector and the vibrant strength of the UK’s life science ecosystem.

Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister, today launched Labour’s Life Sciences Strategy at Stevenage Bioscience Catalyst (SBC) and witnessed at first hand how SBC is scaling up scientific research and using the latest technologies to revolutionise future healthcare.

Shadow_Labour_Minister_Visit_to_SBC_-_Jan_2024.jpg
© Stevenage Bioscience Catalyst Shadow Labour Minister's  visit to SBC, January 2024

The campus at Gunnels Wood Road hosts one of GSK’s two main global research and development facilities, the Cell and Gene Therapy Catapult Manufacturing Centre and Stevenage Bioscience Catalyst, a leading UK location for start-ups and established companies to develop and commercialise cutting edge therapeutics. This co-location of R&D and manufacturing facilities is unique within the Golden Research Triangle of Oxford-Cambridge-London. This enables companies to move from start-up to scale up and the commercialisation of potentially life-saving therapeutics.

In 2020, the Stevenage campus was awarded Life Sciences Opportunity Zone status by the Government and High Potential Opportunity status for its excellence in cell and gene therapy by the Department for Business and Trade.  It is now a leading life science cluster with a world-recognised specialism in cell and gene therapy.

The Shadow Ministers were greeted by Stevenage Bioscience Catalyst CEO Dr Sally Ann Forsyth OBE who led them on a tour of SBC’s facilities.  SBC is home to over 40 companies, which since opening in 2011, have raised over £3 billion in funding, with Stevenage, a relative newcomer, now on a par for equity raised on biotechnology (2017-2020) with the more established life science clusters of Oxford, Cambridge, and London.

Early-stage innovation is nurtured at SBC’s Lab Hotel which provides fledgling start-ups with rent-free space for six months. Wes Streeting and Peter Kyle met with the CEOs of three current Lab Hotel occupiers: Genevation which is developing anti-cancer vaccines; Vasodynamics, which is helping patients with the side effects from chemotherapy and Plurify which is advancing cell and gene therapy for a range of future treatments. They also met with Complement Therapeutics which successfully raised over €72 million funding in 2023 to help tackle vision loss in older people and other eye conditions. 

Following the tour, the Labour Ministers took part in a roundtable discussion with leaders from SBC, AstraZeneca, GSK, BioIndustry Association (BIA) together with two of SBC’s high growth companies Complement Therapeutics and Autifony Therapeutics to discuss some of the biggest opportunities and challenges facing the sector. This provided Labour with valuable feedback on their plans to support the sector’s start-ups, scale-ups, and established companies.  

Labour has announced that if elected it would increase investment in research and development in the pharmaceutical sector by £10 billion a year. The focus will be on the development of next generation medical treatments such as cell and gene therapy, mRNA vaccines and the use of AI in healthcare – all very much in evidence today at SBC.

Dr Sally Ann Forsyth OBE, said: "The fact that Labour chose to launch their Life Sciences Strategy here in Stevenage demonstrates that the innovation happening on campus is powering the UK economy and the next generation of healthcare. This was a great opportunity to showcase some of the fantastic science taking place at SBC and also to have a frank and open conversation about the challenges facing our sector."

Peter Kyle, Shadow Secretary of State for Science, Innovation and Technology, said: "If we get this right, we can transform the NHS so that it becomes an engine of innovation, a driver of growth and a public service that once again delivers world class outcomes for patients. Labour will work hand in glove with life sciences companies to tackle the biggest killers, reduce the number of lives lost to heart disease, stroke and cancer and create thousands of new jobs across the country."

Wes Streeting, Shadow Secretary of State for Health and Social Care, said: "The life sciences are key to our mission for an NHS fit for the future and pioneering breakthroughs that will transform and extend lives for the better.  This plan will ensure that NHS patients get better care and that more life-saving medicines are developed right here in the UK to help people live better lives."

Steve Bates OBE, CEO of the BioIndustry Association, said: "Innovative small companies are the innovation drivers for the life sciences industry and facilities like Stevenage Bioscience Catalyst provide them with valuable support on their scaling journey. The plans set out by Labour today will help ensure sites like this can continue to deliver economic growth for their local communities and innovative medicines for the world."

 

More news and updates 

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

Coulter Partners top hires for VC & PE portfolio companies Q1-2024

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

Abzena announces major investment in bioconjugation and ADC capabilities in response to increasing industry demand

Abzena announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.

New £6.2 million partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya

A new £6.2 million healthcare project has begun in Kenya to advance elimination of visceral leishmaniasis, a deadly parasitic disease found in Africa, the Americas, the Middle East and South-East Asia, which affects up to 90,000 children and vulnerable people globally.

New study explores how Switzerland can maintain its leading position in life science innovation

The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity Reports: “Sustaining a winning position”, an analysis of how Switzerland can continue to lead the life sciences sector in a shifting global market.

Data from Brainomix’s collaboration with AstraZeneca shows e-Lung better identifies lung fibrosis patients at risk of decline

Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix’s AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.

Eight things we learned about commercialising medical research at Imperial's 'All You Can Innovate' 2024

Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.

PrecisionLife and NATA announce R&D partnership to jointly develop new motor neurone disease

Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS. The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development.

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team

Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

 

More within